Viewing StudyNCT05025735



Ignite Creation Date: 2024-05-06 @ 4:33 PM
Last Modification Date: 2024-10-26 @ 2:12 PM
Study NCT ID: NCT05025735
Status: UNKNOWN
Last Update Posted: 2021-10-19
First Post: 2021-06-26

Brief Title: Alpelisib Fulvestrant and Dapagliflozin for the Treatment of HR HER2 - PIK3CA Mutant Metastatic Breast Cancer
Sponsor: Saint Lukes Health System
Organization: Saint Lukes Health System

Conditions & Keywords Data

Conditions:
Name
Metastatic Breast Cancer
HER2-negative Breast Cancer
Keywords:
Name View
Metastatic Breast Cancer View
HER2 Negative View
HR Positive View